 Ann Kulungowski
Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 10 | 2026 | 52 | 4.660 |
Why?
| | Lymphatic Abnormalities | 3 | 2020 | 20 | 1.550 |
Why?
| | Hemangioma | 7 | 2025 | 46 | 1.190 |
Why?
| | Sclerotherapy | 2 | 2018 | 19 | 1.040 |
Why?
| | Pneumatosis Cystoides Intestinalis | 2 | 2024 | 21 | 0.930 |
Why?
| | Secondary Prevention | 2 | 2018 | 251 | 0.920 |
Why?
| | Wounds, Penetrating | 2 | 2023 | 72 | 0.840 |
Why?
| | Surgical Wound | 1 | 2023 | 27 | 0.750 |
Why?
| | Chylous Ascites | 1 | 2022 | 5 | 0.740 |
Why?
| | Chylothorax | 1 | 2022 | 20 | 0.730 |
Why?
| | Liver Neoplasms | 7 | 2025 | 777 | 0.730 |
Why?
| | Neutropenia | 1 | 2023 | 154 | 0.730 |
Why?
| | Respiration Disorders | 1 | 2022 | 78 | 0.700 |
Why?
| | Surgeons | 2 | 2025 | 340 | 0.690 |
Why?
| | Wounds, Nonpenetrating | 3 | 2019 | 321 | 0.660 |
Why?
| | Intestines | 2 | 2022 | 354 | 0.610 |
Why?
| | Surgery Department, Hospital | 2 | 2016 | 22 | 0.600 |
Why?
| | Hypovolemia | 1 | 2019 | 12 | 0.580 |
Why?
| | Pediatric Emergency Medicine | 1 | 2019 | 24 | 0.580 |
Why?
| | Vertebral Artery | 1 | 2019 | 26 | 0.580 |
Why?
| | Infant | 24 | 2026 | 10091 | 0.580 |
Why?
| | Carotid Artery Injuries | 1 | 2019 | 39 | 0.580 |
Why?
| | Doxycycline | 1 | 2018 | 62 | 0.550 |
Why?
| | Medical Errors | 1 | 2019 | 119 | 0.530 |
Why?
| | Child | 25 | 2026 | 22740 | 0.510 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 179 | 0.500 |
Why?
| | Hospital Rapid Response Team | 1 | 2016 | 20 | 0.480 |
Why?
| | Sclerosing Solutions | 1 | 2016 | 10 | 0.480 |
Why?
| | Infant, Newborn | 16 | 2025 | 6465 | 0.480 |
Why?
| | Veins | 1 | 2016 | 69 | 0.470 |
Why?
| | Bevacizumab | 1 | 2016 | 168 | 0.450 |
Why?
| | Patient Safety | 1 | 2019 | 356 | 0.440 |
Why?
| | Interferon-alpha | 1 | 2016 | 193 | 0.440 |
Why?
| | Ileal Diseases | 1 | 2014 | 14 | 0.430 |
Why?
| | Gastrostomy | 2 | 2026 | 130 | 0.410 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 558 | 0.390 |
Why?
| | Rectum | 2 | 2015 | 182 | 0.390 |
Why?
| | Child Abuse | 1 | 2019 | 553 | 0.380 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2933 | 0.380 |
Why?
| | Child, Preschool | 17 | 2026 | 11868 | 0.370 |
Why?
| | Receptors, Somatotropin | 1 | 2012 | 10 | 0.370 |
Why?
| | Humans | 44 | 2026 | 145783 | 0.340 |
Why?
| | Genital Neoplasms, Male | 1 | 2011 | 4 | 0.340 |
Why?
| | Genitalia, Male | 1 | 2011 | 11 | 0.340 |
Why?
| | Blood Transfusion | 4 | 2022 | 409 | 0.340 |
Why?
| | Patients | 2 | 2023 | 183 | 0.340 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 19 | 0.340 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 649 | 0.330 |
Why?
| | Disease Management | 1 | 2015 | 653 | 0.330 |
Why?
| | Registries | 4 | 2025 | 2410 | 0.330 |
Why?
| | Receptors, Androgen | 1 | 2012 | 149 | 0.330 |
Why?
| | Crohn Disease | 1 | 2014 | 260 | 0.330 |
Why?
| | Neoplasms | 2 | 2024 | 2913 | 0.330 |
Why?
| | Blood Vessels | 1 | 2012 | 167 | 0.330 |
Why?
| | Arteriovenous Malformations | 2 | 2026 | 33 | 0.320 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 244 | 0.320 |
Why?
| | Retrospective Studies | 19 | 2026 | 17330 | 0.320 |
Why?
| | Adolescent | 17 | 2026 | 22577 | 0.320 |
Why?
| | HELLP Syndrome | 1 | 2009 | 5 | 0.310 |
Why?
| | Mesenteric Veins | 1 | 2010 | 24 | 0.310 |
Why?
| | Hemangioendothelioma | 2 | 2025 | 13 | 0.310 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 243 | 0.300 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 404 | 0.290 |
Why?
| | Portal Vein | 1 | 2010 | 117 | 0.290 |
Why?
| | Skin Neoplasms | 3 | 2025 | 853 | 0.270 |
Why?
| | Venous Thrombosis | 1 | 2010 | 196 | 0.270 |
Why?
| | Laparoscopy | 2 | 2026 | 481 | 0.270 |
Why?
| | Port-Wine Stain | 1 | 2026 | 4 | 0.240 |
Why?
| | Klippel-Trenaunay-Weber Syndrome | 1 | 2026 | 5 | 0.240 |
Why?
| | Bone Transplantation | 3 | 2012 | 89 | 0.240 |
Why?
| | Gastropexy | 1 | 2026 | 4 | 0.240 |
Why?
| | Capillaries | 1 | 2026 | 125 | 0.220 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2025 | 8 | 0.220 |
Why?
| | Sutures | 1 | 2025 | 66 | 0.220 |
Why?
| | Anticoagulants | 1 | 2010 | 748 | 0.210 |
Why?
| | Suture Techniques | 1 | 2025 | 137 | 0.210 |
Why?
| | Hemorrhage | 1 | 2009 | 822 | 0.210 |
Why?
| | Sarcoma, Kaposi | 1 | 2025 | 83 | 0.200 |
Why?
| | Recurrence | 2 | 2018 | 1139 | 0.200 |
Why?
| | Specialties, Surgical | 1 | 2025 | 82 | 0.200 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1925 | 0.200 |
Why?
| | Phlebography | 2 | 2016 | 41 | 0.200 |
Why?
| | Male | 26 | 2026 | 73010 | 0.200 |
Why?
| | Physicians, Women | 1 | 2025 | 90 | 0.200 |
Why?
| | Hepatoblastoma | 1 | 2024 | 52 | 0.190 |
Why?
| | Treatment Outcome | 8 | 2024 | 11794 | 0.190 |
Why?
| | Craniotomy | 3 | 2012 | 84 | 0.190 |
Why?
| | Radiography, Interventional | 1 | 2024 | 128 | 0.190 |
Why?
| | Postoperative Complications | 2 | 2026 | 2977 | 0.190 |
Why?
| | Lymphedema | 2 | 2014 | 22 | 0.190 |
Why?
| | Ascites | 1 | 2022 | 48 | 0.180 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.180 |
Why?
| | Noonan Syndrome | 1 | 2022 | 14 | 0.180 |
Why?
| | Parietal Bone | 2 | 2012 | 9 | 0.180 |
Why?
| | Female | 23 | 2026 | 79045 | 0.180 |
Why?
| | Frontal Bone | 2 | 2012 | 19 | 0.170 |
Why?
| | Radiologists | 1 | 2022 | 61 | 0.170 |
Why?
| | Drainage | 1 | 2022 | 185 | 0.170 |
Why?
| | Rabbits | 4 | 2016 | 653 | 0.170 |
Why?
| | Congenital Abnormalities | 1 | 2022 | 109 | 0.160 |
Why?
| | Incidence | 4 | 2022 | 2934 | 0.160 |
Why?
| | Professional Role | 1 | 2022 | 170 | 0.160 |
Why?
| | Risk Factors | 6 | 2024 | 10919 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 373 | 0.150 |
Why?
| | Skin | 1 | 2025 | 754 | 0.150 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 287 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 329 | 0.150 |
Why?
| | Endovascular Procedures | 1 | 2024 | 390 | 0.140 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.140 |
Why?
| | Duodenostomy | 1 | 2018 | 3 | 0.140 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 19 | 0.140 |
Why?
| | Duodenal Obstruction | 1 | 2018 | 6 | 0.140 |
Why?
| | Duodenum | 1 | 2018 | 77 | 0.130 |
Why?
| | Thoracotomy | 1 | 2018 | 88 | 0.130 |
Why?
| | Thoracic Injuries | 1 | 2018 | 71 | 0.130 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 199 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5428 | 0.130 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 166 | 0.120 |
Why?
| | Healthcare Disparities | 1 | 2024 | 736 | 0.120 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2016 | 15 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2025 | 1202 | 0.120 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 58 | 0.120 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 14 | 0.110 |
Why?
| | Hypotension | 1 | 2016 | 127 | 0.110 |
Why?
| | Shock | 1 | 2016 | 110 | 0.110 |
Why?
| | Pyloric Stenosis, Hypertrophic | 1 | 2015 | 10 | 0.110 |
Why?
| | Drug Carriers | 1 | 2016 | 136 | 0.110 |
Why?
| | Risk Assessment | 3 | 2015 | 3752 | 0.110 |
Why?
| | Catheters, Indwelling | 1 | 2015 | 96 | 0.110 |
Why?
| | Genital Diseases, Male | 1 | 2014 | 16 | 0.110 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 239 | 0.110 |
Why?
| | Penis | 1 | 2014 | 33 | 0.100 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2014 | 35 | 0.100 |
Why?
| | Scrotum | 1 | 2014 | 25 | 0.100 |
Why?
| | Hirschsprung Disease | 1 | 2015 | 92 | 0.100 |
Why?
| | Peritoneal Dialysis | 1 | 2015 | 100 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2022 | 962 | 0.100 |
Why?
| | Neonatal Screening | 1 | 2015 | 179 | 0.100 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 112 | 0.100 |
Why?
| | Gastroenterology | 1 | 2015 | 191 | 0.090 |
Why?
| | Postoperative Care | 1 | 2015 | 286 | 0.090 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1368 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 403 | 0.090 |
Why?
| | Databases, Factual | 2 | 2024 | 1491 | 0.090 |
Why?
| | Bone Resorption | 1 | 2012 | 81 | 0.090 |
Why?
| | Lipomatosis | 1 | 2011 | 4 | 0.090 |
Why?
| | Cheek | 1 | 2011 | 16 | 0.090 |
Why?
| | Hamartoma | 1 | 2012 | 29 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2028 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 293 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 63 | 0.090 |
Why?
| | alpha-Fetoproteins | 1 | 2011 | 42 | 0.090 |
Why?
| | Prospective Studies | 3 | 2012 | 8078 | 0.080 |
Why?
| | Young Adult | 6 | 2015 | 14254 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2219 | 0.080 |
Why?
| | Rare Diseases | 1 | 2011 | 116 | 0.080 |
Why?
| | Biomarkers | 2 | 2012 | 4302 | 0.080 |
Why?
| | Ligation | 1 | 2010 | 91 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6085 | 0.070 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.070 |
Why?
| | Skull | 1 | 2010 | 163 | 0.070 |
Why?
| | Length of Stay | 1 | 2015 | 1350 | 0.070 |
Why?
| | Osteogenesis | 1 | 2010 | 204 | 0.070 |
Why?
| | United States | 2 | 2024 | 16126 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1271 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1723 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4568 | 0.070 |
Why?
| | Pediatrics | 1 | 2015 | 1125 | 0.060 |
Why?
| | Colorado | 1 | 2016 | 4556 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2383 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3916 | 0.060 |
Why?
| | Cellulitis | 1 | 2025 | 54 | 0.060 |
Why?
| | Adult | 4 | 2012 | 40881 | 0.050 |
Why?
| | Massachusetts | 2 | 2014 | 180 | 0.050 |
Why?
| | Age Factors | 2 | 2024 | 3346 | 0.050 |
Why?
| | Vascular System Injuries | 1 | 2024 | 81 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1899 | 0.050 |
Why?
| | Prognosis | 1 | 2011 | 4330 | 0.050 |
Why?
| | Splenectomy | 1 | 2022 | 61 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 126 | 0.040 |
Why?
| | Perioperative Period | 1 | 2022 | 71 | 0.040 |
Why?
| | Esophageal Atresia | 1 | 2022 | 32 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 254 | 0.040 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 40 | 0.040 |
Why?
| | X-Ray Microtomography | 2 | 2012 | 108 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2022 | 125 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 428 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 209 | 0.040 |
Why?
| | Survival Rate | 2 | 2015 | 2094 | 0.040 |
Why?
| | Spleen | 1 | 2022 | 508 | 0.040 |
Why?
| | Animals | 4 | 2016 | 38101 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 467 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 896 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1327 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2110 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 4090 | 0.040 |
Why?
| | Heart Diseases | 1 | 2022 | 341 | 0.030 |
Why?
| | Operative Time | 1 | 2018 | 181 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 162 | 0.030 |
Why?
| | Pregnancy | 1 | 2009 | 7216 | 0.030 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 34 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2865 | 0.030 |
Why?
| | Middle Aged | 3 | 2014 | 36309 | 0.030 |
Why?
| | Dialysis Solutions | 1 | 2015 | 23 | 0.030 |
Why?
| | Resuscitation | 1 | 2018 | 312 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 83 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 191 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 2000 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 204 | 0.030 |
Why?
| | Constipation | 1 | 2015 | 98 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 155 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2016 | 599 | 0.030 |
Why?
| | Heart Arrest | 1 | 2018 | 411 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 403 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 327 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2015 | 280 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 289 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 322 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2015 | 217 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 971 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1082 | 0.020 |
Why?
| | Gestational Age | 1 | 2015 | 990 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1547 | 0.020 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2011 | 20 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 365 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 86 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2011 | 86 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1475 | 0.020 |
Why?
| | Osseointegration | 1 | 2011 | 60 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 74 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1662 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 131 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2139 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2123 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 365 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 979 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 381 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 798 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 668 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 848 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 298 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 552 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 874 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 6033 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 7134 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2601 | 0.010 |
Why?
| | Aged | 1 | 2014 | 26217 | 0.010 |
Why?
|
|
Kulungowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|